Moderna Earnings Call: Cost Cuts, Cash, and Risk

Moderna ((MRNA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Moderna’s latest earnings call painted a picture of disciplined execution against a tougher backdrop. Management showcased sharp cost cuts, a strong MNEXT Spike launch, and a still‑solid cash pile, but also stressed that regulatory setbacks, especially in flu, and event‑driven trial risks cloud the path to near‑term growth.

Revenue and Quarterly Performance

Moderna reported 2025 revenue of $1.9 billion, with Q4 sales of $700 million landing at the high end of guidance. The U.S. contributed $1.2 billion, or about 62% of full‑year revenue, while international markets added $700 million, underscoring continued reliance on the domestic COVID market.

Commercial Launch Success — MNEXT Spike

The MNEXT Spike COVID vaccine launch in the U.S. was a bright spot, capturing 24% of the retail market and 34% among adults 65 and older. Approvals in Canada and Australia, with more targeted, position the product as the core commercial engine while the broader portfolio develops.

Significant Cost Reductions and Efficiency Gains

Management emphasized aggressive cost discipline, with operating expenses down $2.2 billion, or 30%, for the year and 31% lower in Q4 versus last year. Cost of sales dropped 41% to $868 million, R&D fell 31% to $3.1 billion, and SG&A declined 13% to $1.0 billion, beating the original 2025 savings plan by over $1 billion.

Improved Loss Metrics and Strong Cash Position

The company’s net loss narrowed to $2.8 billion from $3.6 billion, with loss per share improving roughly 22% to $7.26. Moderna ended 2025 with $8.1 billion in cash and investments, or $7.6 billion excluding a credit draw, providing a sizable runway despite ongoing losses.

Clear 2026 Financial Framework and Return-to-Growth Guidance

For 2026, management outlined a framework targeting up to 10% revenue growth, driven largely by international markets and a more balanced regional mix. The company expects revenue to be heavily back‑half weighted, with roughly 15% in the first half and 85% in the second half, highlighting seasonal and timing risks for investors.

Pipeline Progress and Clinical Milestones

On the pipeline, Moderna highlighted five‑year phase 2 data for its individualized cancer therapy in adjuvant melanoma, showing about a 50% reduction in relapse or death. Multiple late‑stage oncology trials plus fully enrolled phase 3 programs in norovirus and propionic acidemia set up a slate of important potential readouts in 2026.

Strategic Partnerships and Geographic Expansion

The company is broadening its geographic and product footprint through partnerships and local manufacturing. A new five‑year supply agreement with Mexico, commercialization with Recordati for a rare disease therapy, and local production deals in the U.K., Canada, and Australia are expected to contribute meaningfully from 2026 onward.

FDA Refusal to File on Flu Vaccine

A key negative from the call was the U.S. regulator’s refusal to file Moderna’s seasonal flu vaccine application, which management called a major disappointment. The company has requested a follow‑up meeting, but the timeline and requirements to resubmit remain unclear, raising questions around U.S. flu market entry.

Revenue Dependency and Conservative Assumptions

Because of flu uncertainty, the 2026 outlook assumes no U.S. revenue from the standalone flu vaccine or the flu‑COVID combo. That leaves near‑term growth dependent on COVID products, MNEXT Spike, and partner‑driven revenues, with about 85% of annual sales concentrated in the second half of the year.

Continued Net Loss and Cash Decline Outlook

Despite improvement, Moderna is still burning cash, with a $2.8 billion net loss in 2025 and cash falling from $9.5 billion to $8.1 billion. Management expects cash and investments to decline further to $5.5–6.0 billion by the end of 2026, even without additional credit draws, underscoring the importance of successful launches and pipeline execution.

Cost of Sales Decline and Demand Headwinds

The sharp 41% drop in cost of sales reflects not just productivity gains but also lower inventory write‑downs, the wind‑down of contract manufacturing, and reduced volumes. This mix suggests that while operations are leaner, underlying demand for some products has softened, raising questions about long‑term scale.

Regulatory Uncertainty and U.S. Market Timing

Management voiced broader concerns about U.S. regulatory unpredictability, warning that approvals could increasingly arrive abroad before the domestic market. Such delays could push earlier commercialization into ex‑U.S. regions, complicating forecasting and potentially reshaping where Moderna’s future revenue is generated.

Dependence on Event-Driven Clinical Readouts

Many of Moderna’s key value drivers, especially in oncology and norovirus, are tied to event‑driven trials, where timing depends on accruing clinical endpoints. Several pivotal readouts are anticipated in 2026, but both their dates and outcomes remain inherently uncertain, adding another layer of risk to the investment story.

Revenue Mix Shift and Market Dynamics

The company expects its currently U.S.‑heavy revenue mix to shift toward a more balanced U.S./international profile in 2026. That transition will hinge on approvals, tender wins, and pricing in multiple markets, where uptake patterns and reimbursement dynamics can vary widely and affect actual realized growth.

Guidance and Forward-Looking Outlook

Looking ahead, Moderna’s 2026 framework calls for up to 10% revenue growth, flat cost of sales around $900 million yet better margins, and R&D at roughly $3.0 billion with SG&A steady at $1.0 billion. With cash costs near $4.2 billion, modest capex, and year‑end cash guided to $5.5–6.0 billion, the company is betting that pipeline milestones and international expansion will offset U.S. flu delays.

Moderna’s earnings call blended encouraging operational progress with clear caution flags that investors cannot ignore. Strong COVID market share, deep cost cuts, and a robust late‑stage pipeline offer upside, but regulatory uncertainty, concentrated revenues, and ongoing cash burn mean the path back to durable growth remains challenging and execution‑dependent.